Celltrion, Inc. and CSL Limited Announce Collaboration to Develop and Manufacture Monoclonal Antibody
INCHEON, South Korea, Jan. 10 /PRNewswire/ -- Celltrion, Inc., a Korean biopharmaceutical company whose core business is currently contract manufacturing, and CSL Limited, Australia's leading biopharmaceutical company, announced today the signing of an agreement for the development and supply of CSL 360, an experimental monoclonal antibody therapy for the treatment of acute myeloid leukemia (AML). Phase I clinical trials for CSL 360 are currently being conducted by CSL in Australia.
As part of the collaboration, Celltrion will provide process development expertise and supply clinical and commercial material to support the clinical development program for CSL 360 and commercialization of the product, with the potential for a longer term strategic manufacturing relationship between the companies in the future.
"Celltrion and its employees are completely committed to world-class quality in biopharmaceutical manufacturing, to assisting CSL in achieving the successful completion of clinical trials, and to providing manufacturing support for CSL's product commercialization," said Jung-Jin Seo, Celltrion's Chairman and Chief Executive Officer.
"Superior quality biopharmaceutical manufacturing facilities of this type are a scarce commodity in this region and we are delighted to have signed this collaboration to provide CSL with the opportunity to facilitate the clinical development of CSL 360 and potentially other exciting future recombinant protein opportunities," said Dr. Brian McNamee, CSL's Chief Executive Officer.
About Celltrion
Celltrion, established in 2002, is a contract manufacturing organization with a headquarters in Incheon, South Korea. Celltrion, an emerging leader in the biopharmaceutical industry, is dedicated to providing high quality services to accelerate product development, while offering scalable manufacturing capabilities for our clients and business partners. Celltrion is also investing in research and development of its own products, as well as licensing from biopharmaceutical research companies throughout the world, in order to develop into a fully integrated biotechnology company. For more information, please visit Celltrion's website at http://www.celltrion.com.
About CSL Limited
Headquartered in Melbourne, Australia, CSL Limited is a global, specialty biopharmaceutical company that develops, manufactures and markets protein-based medicines to treat and prevent serious human medical conditions. The CSL Group has a combined heritage of outstanding contributions to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies. Our strong commitment to funding research and development of protein based biological medicines for unmet medical needs underpins our continuing growth.
The CSL Group includes CSL Bioplasma, CSL Biotherapies and CSL Behring incorporating ZLB Plasma. With major facilities in Australia, Germany, Switzerland and the U.S., CSL has over 8,600 employees operating in 27 countries.
seungsuh.hong@celltrion.com
CONTACT: Seung-Suh Hong, Ph.D., Senior Vice President - Business
Development of Celltrion, Inc. (U.S.A.), +1-650-766-2307,
seungsuh.hong@celltrion.com
Web site: http://www.celltrion.com/